Grifols’ Q2 20 top-line growth remained resilient amid the pandemic, primarily driven by the robust demand for plasma-driven medicines. However, population confinements lowered plasma collection across the globe, in turn impacting the group’s profitability. Though plasma collection might remain a challenge until herd immunity is achieved, rising unemployment and GC Pharma’s acquisition should provide some respite. A positive result on convalescent plasma trial on COVID-19 wo
31 Jul 2020
Lower plasma collection overshadows the solid performance in Q2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lower plasma collection overshadows the solid performance in Q2
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
31 Jul 2020 -
Author:
Rishabh Kochar -
Pages:
3
Grifols’ Q2 20 top-line growth remained resilient amid the pandemic, primarily driven by the robust demand for plasma-driven medicines. However, population confinements lowered plasma collection across the globe, in turn impacting the group’s profitability. Though plasma collection might remain a challenge until herd immunity is achieved, rising unemployment and GC Pharma’s acquisition should provide some respite. A positive result on convalescent plasma trial on COVID-19 wo